Literature DB >> 11531959

Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses.

N Sami1, K C Bhol, A R Ahmed.   

Abstract

There are several studies that describe the simultaneous presence and conversion of pemphigus foliaceus into pemphigus vulgaris and vice versa. We describe eight patients with clinical, histological and immunopathological features of pemphigus foliaceus, at the time of the initial diagnosis. After a mean period of 2.5 years, additional serological features of pemphigus vulgaris were observed. During a long-term follow-up, systemic therapies, their durations and treatment outcomes were recorded. These patients did not respond to conventional systemic therapy and developed multiple side-effects from these drugs. Hence, they were treated with intravenous immunoglobulin therapy (IVIg). Prior to the initiation of IVIg therapy, different assays were performed to detect the presence of autoantibodies, including indirect immunofluorescence (IIF), immunoblot assay using bovine gingival lysate, and ELISA. Twenty-five healthy normal individuals, 12 patients with pemphigus vulgaris, and eight patients with pemphigus foliaceus served as controls for comparison of serological studies. At the time of initial diagnosis, the sera of all eight study patients also demonstrated binding on an immunoblot assay to a 160-kDa protein (desmoglein 1) only. This is typically observed in pemphigus foliaceus. Prior to staring IVIg therapy, binding was observed to both the 160 kDa and 130 kDa (desmoglein 3) proteins on an immunoblot assay which was characteristic of pemphigus vulgaris. The antidesmogleins, 1 and 3 autoantibodies, were predominantly of the IgG4 subclass in all eight patients studied. IVIg therapy induced remission in four patients and control in four of the eight patients. The total follow-up period ranged from 2.6 to 9.5 years (mean 5.3 years). It is difficult to determine the exact time at which these patients with pemphigus foliaceus developed pemphigus vulgaris. It is possible that the disease was nonresponsive to conventional immunosuppressive therapy owing to the simultaneous presence of two autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11531959      PMCID: PMC1906144          DOI: 10.1046/j.1365-2249.2001.01637.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

Review 1.  Management of refractory rheumatoid arthritis.

Authors:  L B van de Putte; E J Kroot; P L van Riel
Journal:  Rheumatology (Oxford)       Date:  1999-11       Impact factor: 7.580

Review 2.  Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders.

Authors:  J A Cohen; J L Carter; R P Kinkel; S R Schwid
Journal:  J Neuroimmunol       Date:  1999-07-01       Impact factor: 3.478

3.  Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus.

Authors:  Y Futei; M Amagai; K Ishii; K Kuroda-Kinoshita; K Ohya; T Nishikawa
Journal:  J Dermatol Sci       Date:  2001-05       Impact factor: 4.563

4.  Pemphigus. Epidemiologic and survival characteristics of 59 patients, 1955-1973.

Authors:  L S Krain
Journal:  Arch Dermatol       Date:  1974-12

5.  Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study.

Authors:  C S Foster; A R Ahmed
Journal:  Ophthalmology       Date:  1999-11       Impact factor: 12.079

Review 6.  Epitope spreading: a mechanism for progression of autoimmune disease.

Authors:  V K Tuohy; R P Kinkel
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2000       Impact factor: 4.291

7.  Bovine gingival lysate: a novel substrate for rapid diagnosis of autoimmune vesiculo-bullous diseases. A preliminary observation.

Authors:  L Engineer; R E Johnson; K C Bhol; A R Ahmed
Journal:  Exp Dermatol       Date:  2000-08       Impact factor: 3.960

8.  Development of pemphigus vulgaris in a patient with pemphigus foliaceus: antidesmoglein antibody profile shift confirmed by enzyme-linked immunosorbent assay.

Authors:  K Ishii; M Amagai; Y Ohata; H Shimizu; T Hashimoto; K Ohya; T Nishikawa
Journal:  J Am Acad Dermatol       Date:  2000-05       Impact factor: 11.527

9.  Pemphigus: a 20-year review of 107 patients treated with corticosteroids.

Authors:  F R Rosenberg; S Sanders; C T Nelson
Journal:  Arch Dermatol       Date:  1976-07

10.  Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus.

Authors:  M Amagai; K Tsunoda; H Suzuki; K Nishifuji; S Koyasu; T Nishikawa
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

View more
  3 in total

1.  High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders.

Authors:  S Jolles
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

Review 2.  High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases.

Authors:  Norito Ishii; Takashi Hashimoto; Detlef Zillikens; Ralf J Ludwig
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

3.  A Case of Concomitant Pemphigus Foliaceus and Oral Pemphigus Vulgaris.

Authors:  Alexandra C Perks; Paula M Farthing; Ruth Murphy; Anne M Hegarty
Journal:  Head Neck Pathol       Date:  2018-01-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.